Back to Search Start Over

Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.

Authors :
Tiong IS
Dillon R
Ivey A
Teh TC
Nguyen P
Cummings N
Taussig DC
Latif AL
Potter NE
Runglall M
Russell NH
Raj K
Schwarer AP
Fong CY
Grigg AP
Wei AH
Source :
British journal of haematology [Br J Haematol] 2021 Mar; Vol. 192 (6), pp. 1026-1030. Date of Electronic Publication: 2020 May 26.
Publication Year :
2021

Abstract

Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1 <superscript>mut</superscript> measurable residual disease (MRD) using off-label venetoclax in combination with low-dose cytarabine or azacitidine. Twelve consecutive patients were retrospectively identified, including five with molecular persistence and seven with molecular relapse/progression. All patients with molecular persistence achieved durable molecular complete remission (CR <subscript>MRD-</subscript> ) without transplantation. Six of seven patients with molecular relapse/progression achieved CR <subscript>MRD-</subscript> after 1-2 cycles of venetoclax. This paper highlights the promising efficacy of venetoclax-based therapy to reduce the relapse risk in patients with persistent or rising NPM1 <superscript>mut</superscript> MRD.<br /> (© 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)

Details

Language :
English
ISSN :
1365-2141
Volume :
192
Issue :
6
Database :
MEDLINE
Journal :
British journal of haematology
Publication Type :
Academic Journal
Accession number :
32458446
Full Text :
https://doi.org/10.1111/bjh.16722